Enterprise Value
590.7M
Cash
129.6M
Avg Qtr Burn
-35.36M
Short % of Float
17.48%
Insider Ownership
21.52%
Institutional Own.
70.57%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
VOQUEZNA (Vonoprazan) (Potassium competitive acid blocker) Details Bacterial infection | Approved Quarterly sales | |
Vonoprazan (Potassium competitive acid blocker) Details Intestinal infection, Esophagitis, Gastroesophageal reflux disease | NDA Acceptance for review | |
Vonoprazan (Potassium competitive acid blocker) Details Intestinal infection | Phase 3 Update |